Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.
about
Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.Combined analysis of genome scans of dutch and finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16qInsulin resistance and familial dyslipidaemias.Impaired activation of adipocyte lipolysis in familial combined hyperlipidemiaFamilies with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotypeGenomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels.Association of stearoyl-CoA desaturase 1 activity with familial combined hyperlipidemia.Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance.Unsaturated Oral Fat Load Test Improves Glycemia, Insulinemia and Oxidative Stress Status in Nondiabetic Subjects with Abdominal Obesity.Dyslipidemia in obesity: mechanisms and potential targetsCombined hyperlipidemia in relation to race/ethnicity, obesity, and insulin resistance in the Multi-Ethnic Study of Atherosclerosis.Statin myopathy as a metabolic muscle disease.Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes.Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.Plasma acylation stimulating protein (ASP) as a predictor of impaired cellular biological response to ASP in patients with hyperapoB.Regulation of the plasma non-esterified fatty acid concentration in the postprandial state.Determinants of low HDL levels in familial combined hyperlipidemia.Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia.Fasting acylation-stimulating protein is predictive of postprandial triglyceride clearance.Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients.Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile.The Gln223Arg polymorphism in the leptin receptor is associated with familial combined hyperlipidemia.Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids. I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles.Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids.Hemodynamic effects of lipids in humans.
P2860
Q33619852-506855F3-63C2-42F0-B9D5-AA9ADFBCF04CQ33727061-C8E7222B-266F-4926-A15B-37BF429D6CBBQ33905086-83266D9F-1D17-4C17-ACE5-75937E14A613Q34166298-7D961D54-56BF-4E1C-9393-2B3240C25313Q34217328-4F4C266E-0D16-4EC6-AC74-7C5EAA178DABQ34386695-C729D98A-9CB2-4A94-8B49-3318419D2C80Q34389639-DB227077-AB9F-459F-81AB-10EC808F0421Q34761622-01D54BA9-9262-4CAD-B796-2CC069260B8FQ35186665-AA1C318A-CA3B-415F-8201-CA98F4E90477Q36107154-5CEDD6CD-FAFE-47DC-9777-08A9B82A31BCQ36994072-C4E75F11-93AE-4438-BF5A-1921804A6ED8Q37181649-198FF3FC-D7B1-49F0-9B9F-8D7D696F998FQ37230388-C5E0504E-5754-40F8-8577-01B13EABC2B7Q37364446-2C9BA6DA-1929-4C80-A6AD-8973B9C5DB76Q38839105-18CD0F09-40A5-405C-9A53-97FB776891AFQ41003668-C469905C-96AD-4821-AEDE-A7738B64D46EQ41571831-C3CC58E3-3587-4ADD-959F-1FCB7AC0C1B1Q44460212-1C5F9C48-3611-4C52-8265-700A89B9E6DFQ44552183-D0E4DBCC-606F-4B2E-97FF-A3822294F7DFQ44620944-6699F705-5A09-406F-93A0-F08CE5B9D961Q46024732-D5E99994-9976-4369-AAA8-62C4D52089D0Q46655152-DC675823-DA26-4B54-B53A-A2F49DDBA863Q46908176-E68D8511-FF03-41DF-93CE-7451838E547DQ51031951-CA09B233-2BD6-4083-B673-FDE47D4C6161Q53959743-492951E3-822C-4290-BD1E-DC4A0CDBC9B1Q54009754-D9A4D88B-A8AF-4D08-B7EE-AA06AC0D733C
P2860
Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.
description
1993 nî lūn-bûn
@nan
1993 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Impaired fatty acid metabolism ...... uction and insulin resistance.
@ast
Impaired fatty acid metabolism ...... uction and insulin resistance.
@en
Impaired fatty acid metabolism ...... uction and insulin resistance.
@nl
type
label
Impaired fatty acid metabolism ...... uction and insulin resistance.
@ast
Impaired fatty acid metabolism ...... uction and insulin resistance.
@en
Impaired fatty acid metabolism ...... uction and insulin resistance.
@nl
prefLabel
Impaired fatty acid metabolism ...... uction and insulin resistance.
@ast
Impaired fatty acid metabolism ...... uction and insulin resistance.
@en
Impaired fatty acid metabolism ...... uction and insulin resistance.
@nl
P2093
P2860
P921
P356
P1476
Impaired fatty acid metabolism ...... uction and insulin resistance.
@en
P2093
Castro Cabezas M
Shoulders CC
Willem Erkelens D
de Bruin TW
de Valk HW
P2860
P304
P356
10.1172/JCI116544
P407
P577
1993-07-01T00:00:00Z